These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 10722479)

  • 21. Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.
    Richardson DC; Bast D; McGeer A; Low DE
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1911-4. PubMed ID: 11353652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
    Pan XS; Yague G; Fisher LM
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Korzheva N; Davies TA; Goldschmidt R
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
    Pan XS; Ambler J; Mehtar S; Fisher LM
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2321-6. PubMed ID: 8891138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in the gyrA and parC genes associated with fluoroquinolone resistance in clinical isolates of Citrobacter freundii.
    Nishino Y; Deguchi T; Yasuda M; Kawamura T; Nakano M; Kanematsu E; Ozeki S; Kawada Y
    FEMS Microbiol Lett; 1997 Sep; 154(2):409-14. PubMed ID: 9311142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
    Heaton VJ; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci.
    Ferrándiz MJ; Oteo J; Aracil B; Gómez-Garcés JL; De La Campa AG
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2520-3. PubMed ID: 10508036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.
    Bébéar CM; Grau O; Charron A; Renaudin H; Gruson D; Bébéar C
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2719-27. PubMed ID: 10991851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms and spread of fluoroquinolone resistance in Streptococcus pneumoniae.
    Varon E; Gutmann L
    Res Microbiol; 2000; 151(6):471-3. PubMed ID: 10961461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae.
    Deguchi T; Fukuoka A; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Ban Y; Kawada Y
    Antimicrob Agents Chemother; 1997 Mar; 41(3):699-701. PubMed ID: 9056017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
    Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
    Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis of regions determining resistence to fluoroquinolones in genes gyrA and parC in clinical isolates of Mycoplasma hominis].
    Gushchin AE; Ladygina VG; Govorun VM; Taraskina AM; Savicheva AM
    Mol Gen Mikrobiol Virusol; 2000; (4):33-5. PubMed ID: 11186458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistance.
    Yan SS; Fox ML; Holland SM; Stock F; Gill VJ; Fedorko DP
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3196-8. PubMed ID: 11036052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.
    Janoir C; Zeller V; Kitzis MD; Moreau NJ; Gutmann L
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2760-4. PubMed ID: 9124836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
    Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
    Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.
    Balsalobre L; de la Campa AG
    Antimicrob Agents Chemother; 2008 Mar; 52(3):822-30. PubMed ID: 18160515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoroquinolone resistance in Streptococcus pneumoniae from a university hospital, Thailand.
    Srifuengfung S; Tribuddharat C; Chokephaibulkit K; Comerungsee S
    J Med Assoc Thai; 2010 Nov; 93 Suppl 5():S35-9. PubMed ID: 21298832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae?
    Harding I; Simpson I
    J Chemother; 2000 Oct; 12 Suppl 4():7-15. PubMed ID: 11131958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.